Analysis Of Income And Expense [Abstract]

Pharming Group N.V. - Filing #5829944

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
297,200,000 USD
245,316,000 USD
Material income and expense [abstract]
Research and development expense
83,147,000 USD
68,914,000 USD
Finance income (cost)
1,889,000 USD
6,336,000 USD
Sales and marketing expense
118,802,000 USD
124,049,000 USD
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
11,980,000 USD
5,936,000 USD
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates accounted for using equity method
1,760,000 USD
289,000 USD
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
23,742,000 USD
USD
USD
10,346,000 USD
13,396,000 USD
USD
3,445,000 USD
10,548,000 USD
USD
7,103,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.